# OnCo record paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015" ;
  schema:name "AETHERA: brentuximab vedotin consolidation after autologous stem cell transplantation in Hodgkin lymphoma at risk of relapse"@en ;
  schema:description "Giving the antibody-drug conjugate brentuximab vedotin for up to a year after a stem cell transplant roughly doubled the time before Hodgkin lymphoma came back in patients at high risk of relapse."@en ;
  schema:url <https://onco.cc/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(15)60165-9>, <https://pubmed.ncbi.nlm.nih.gov/25796459/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(15)60165-9> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Moskowitz CH, Nademanee A, Masszi T, et al." ;
  onco:cancers <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:trials <https://onco.cc/trials/aethera/> ;
  onco:journals <https://onco.cc/journals/lancet/> .